- Home
- ZBAI vs APM Comparison
ZBAI vs APM Comparison
Compare ZBAI & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | APM |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 10.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ZBAI | APM |
|---|---|---|
| Price | $5.50 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 52.6K |
| Earning Date | 12-15-2025 | 12-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 93.55 | N/A |
| 52 Week Low | $4.83 | $0.69 |
| 52 Week High | $45.00 | $7.49 |
Technical Indicators
Market Signals| Indicator | ZBAI | APM |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 38.74 |
| Support Level | $5.11 | $1.08 |
| Resistance Level | $9.39 | $1.15 |
| Average True Range (ATR) | 0.84 | 0.10 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 33.64 | 12.50 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.